Karyopharm Therapeutics, Inc. (KPTI)
8.785
-0.06
(-0.73%)
USD |
NASDAQ |
May 08, 14:11
Karyopharm Therapeutics Research and Development Expense (Annual) : 125.32M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences, Inc. | 5.688B |
| Catalyst Pharmaceuticals, Inc. | 12.71M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Oncolytics Biotech, Inc. | 13.31M |
| Agios Pharmaceuticals, Inc. | 334.36M |